Date:9/14/2011

e III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to obtain regulatory approval in foreign markets and adoption and use of the chemosaturation system in such markets, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

Media Contact:Doug Sherk/Gregory Gin

Janine McCargoEVC Group

EVC Group415-568-4887/646-445-4801

646-688-0425
'/>"/>

SOURCE Delcath Systems, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
2. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
3. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
4. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
5. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
6. Delcath Systems, Inc. Announces the Sale of 5,000,000 Shares of Common Stock
7. Delcath on Preliminary List of Additions to Russell Microcap® Index
8. Delcath to Present at the JMP Securities Research Conference
9. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
10. Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT™ Delivery System
11. Delcath to Update Investors on FDA Meeting